ClinicalTrials.gg
CompletedNCT01548404Updated Aug 10, 2018Results posted

Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis

A Phase 2 interventional study of Placebo and Dupilumab in Atopic Dermatitis, sponsored by Regeneron Pharmaceuticals. Completed at 21 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-10.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
109
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 50 studies testing dupilumab in Dermatitis, Atopic — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Dermatitis, Atopic.

Enrollment
24th of 50
109 · median 75
Started
2012
with 1 other
Phase 2
7 of 50
none open now
Registered
2nd of 50
by date
Lead sponsor
22 of 50
Regeneron Pharmaceuticals

Among the 50 studies testing dupilumab in Dermatitis, Atopic, this one is the 24th largest by enrollment, is one of 2 that started in 2012, is one of 7 in phase 2, and was the 2nd registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 50 studies testing dupilumab in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing dupilumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The primary objective was to assess the clinical efficacy of repeated subcutaneous (SC) doses of Dupilumab in adult participants with moderate-to-severe atopic dermatitis (AD).

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The inclusion criteria included, but were not limited to the following:

  1. Male or female, 18 years or older;
  2. Chronic Atopic Dermatitis (AD) for at least 3 years;
  3. History of inadequate response to a stable (>/= 1 month) regimen of topical or calcineurin inhibitors as treatment for AD within 3 months before the screening visit.

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with REGN668;
  2. Presence of certain laboratory abnormalities at the screening visit;
  3. Treatment with an drug within 8 weeks ;
  4. Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit;
  5. Certain treatments and medical procedures, undertaken within a particular time-frame prior to the baseline visit, preclude eligibility for participation in the study;
  6. Known history of (HIV) infection;
  7. History of within 5 years before the baseline visit, with certain exceptions;
  8. Planned surgical procedure during the length of the patient's participation in this study;
  9. History of clinical parasite infection;
  10. Any medical or psychiatric condition which in the opinion of the investigator or the sponsor's medical monitor, would place the participant at risk, interfere with participation in the study, or interfere with the interpretation of study results;
  11. Pregnant or breast-feeding women.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
109 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo (for Dupilumab) once weekly for 12 weeks by subcutaneous (SC) injection.

    Drug: Placebo

  • Experimental
    Dupilumab 300 mg

    Dupilumab 300 mg once weekly for 12 weeks by SC injection.

    Drug: Dupilumab

Interventions

  • DrugPlacebo

    Subcutaneous injection altered between back of arms, abdomen and upper thighs.

  • Subcutaneous injection altered between back of arms, abdomen and upper thighs.

    Also known as: REGN668/SAR231893, Dupixent

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 12- Last Observation Carried Forward (LOCF)

    The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. The efficacy data were set to be missing after use of rescue medication and after early termination visit for participants who prematurely discontinued study treatment. All missing values were imputed by LOCF.

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" at Week 12- LOCF

    IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). The efficacy data were set to be missing after use of rescue medication and after early termination visit for participants who prematurely discontinued study treatment. All missing values were imputed by LOCF.

    Time frame: Week 12

  2. Percentage of Participants Who Achieved at Least a 50% Reduction From Baseline in the EASI Score (EASI-50) at Week 12- LOCF

    The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-50 responders were the participants who achieved ≥50% overall improvement in EASI score from baseline to Week 12. The efficacy data were set to be missing after use of rescue medication and after early termination visit for participants who prematurely discontinued study treatment. All missing values were imputed by LOCF.

    Time frame: Week 12

  3. Change From Baseline in EASI Score at Week 12- LOCF

    The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. The efficacy data were set to be missing after use of rescue medication and after early termination visit for participants who prematurely discontinued study treatment. All missing values were imputed by LOCF.

    Time frame: Baseline to Week 12

  4. Percent Change From Baseline in IGA Score at Week 12- LOCF

    IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). The efficacy data were set to be missing after use of rescue medication and after early termination visit for participants who prematurely discontinued study treatment. All missing values were imputed by LOCF.

    Time frame: Baseline to Week 12

  5. Change From Baseline in Percent Body Surface Area (BSA) Affected by Atopic Dermatitis (AD) at Week 12 - LOCF

    BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]). It was reported as a percentage of all major body sections combined. The efficacy data were set to be missing after use of rescue medication and after early termination visit for participants who prematurely discontinued study treatment. All missing values were imputed by LOCF.

    Time frame: Baseline to Week 12

  6. Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Score at Week 12- LOCF

    SCORAD is a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). The efficacy data were set to be missing after use of rescue medication and after early termination visit for participants who prematurely discontinued study treatment. All missing values were imputed by LOCF.

    Time frame: Baseline to Week 12

  7. Change From Baseline in Pruritus Numerical Rating Scale (NRS) to Week 12- LOCF

    Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). The efficacy data were set to be missing after use of rescue medication and after early termination visit for participants who prematurely discontinued study treatment. All missing values were imputed by LOCF.

    Time frame: Baseline to Week 12

  8. Change From Baseline in 5-D Pruritus Scale at Week 12

    The 5-D Pruritus Scale is a 1-page, 5-question tool used in clinical trials to assess 5 dimensions of background itch: degree, duration, direction, disability, and distribution. Each question corresponds to 1 of the 5 dimensions of itch; participants were to rate their symptoms over the preceding 2-week period on a 1 to 5 scale, with 5 being the most affected. After the summation of individual score, the total score ranges from 5 (least affected) to 25 (most affected).

    Time frame: Baseline to Week 12

07

Results

Posted Aug 10, 2018

Participant flow

The study was conducted at 25 sites in Europe between 3 April 2012 and 25 June 2013. A total of 153 participants were screened in the study.

Participant flow — Overall Study
MilestonePlaceboDupilumab 300 mg
Started5455
Completed2441
Not completed3014
Withdrew: Adverse event31
Withdrew: Physician decision21
Withdrew: Inadequate response to study treatment237
Withdrew: Lost to follow-up20
Withdrew: Withdrawal by subject03
Withdrew: Other than specified above02

Outcome measures

PrimaryPercent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 12- Last Observation Carried Forward (LOCF)

The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. The efficacy data were set to be missing after use of rescue medication and after early termination visit for participants who prematurely discontinued study treatment. All missing values were imputed by LOCF.

Time frame:
Baseline to Week 12
Reported as:
Mean · percent change
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 12- Last Observation Carried Forward (LOCF)
percent changePlaceboDupilumab 300 mg
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 12- Last Observation Carried Forward (LOCF)-23.3 ± 49.26-74.0 ± 26.94
SecondaryPercentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" at Week 12- LOCF

IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). The efficacy data were set to be missing after use of rescue medication and after early termination visit for participants who prematurely discontinued study treatment. All missing values were imputed by LOCF.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" at Week 12- LOCF
percentage of participantsPlaceboDupilumab 300 mg
Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" at Week 12- LOCF7.440.0
SecondaryPercentage of Participants Who Achieved at Least a 50% Reduction From Baseline in the EASI Score (EASI-50) at Week 12- LOCF

The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-50 responders were the participants who achieved ≥50% overall improvement in EASI score from baseline to Week 12. The efficacy data were set to be missing after use of rescue medication and after early termination visit for participants who prematurely discontinued study treatment. All missing values were imputed by LOCF.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved at Least a 50% Reduction From Baseline in the EASI Score (EASI-50) at Week 12- LOCF
Percentage of participantsPlaceboDupilumab 300 mg
Percentage of Participants Who Achieved at Least a 50% Reduction From Baseline in the EASI Score (EASI-50) at Week 12- LOCF35.285.5
SecondaryChange From Baseline in EASI Score at Week 12- LOCF

The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. The efficacy data were set to be missing after use of rescue medication and after early termination visit for participants who prematurely discontinued study treatment. All missing values were imputed by LOCF.

Time frame:
Baseline to Week 12
Reported as:
Mean · Units on a scale
Change From Baseline in EASI Score at Week 12- LOCF
Units on a scalePlaceboDupilumab 300 mg
Change From Baseline in EASI Score at Week 12- LOCF-6.4 ± 14.85-19.9 ± 11.52
SecondaryPercent Change From Baseline in IGA Score at Week 12- LOCF

IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). The efficacy data were set to be missing after use of rescue medication and after early termination visit for participants who prematurely discontinued study treatment. All missing values were imputed by LOCF.

Time frame:
Baseline to Week 12
Reported as:
Mean · Percent change
Percent Change From Baseline in IGA Score at Week 12- LOCF
Percent changePlaceboDupilumab 300 mg
Percent Change From Baseline in IGA Score at Week 12- LOCF-14.7 ± 27.37-49.5 ± 25.94
SecondaryChange From Baseline in Percent Body Surface Area (BSA) Affected by Atopic Dermatitis (AD) at Week 12 - LOCF

BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]). It was reported as a percentage of all major body sections combined. The efficacy data were set to be missing after use of rescue medication and after early termination visit for participants who prematurely discontinued study treatment. All missing values were imputed by LOCF.

Time frame:
Baseline to Week 12
Reported as:
Mean · Percentage of BSA
Change From Baseline in Percent Body Surface Area (BSA) Affected by Atopic Dermatitis (AD) at Week 12 - LOCF
Percentage of BSAPlaceboDupilumab 300 mg
Change From Baseline in Percent Body Surface Area (BSA) Affected by Atopic Dermatitis (AD) at Week 12 - LOCF-9.0 ± 21.07-27.4 ± 22.81
SecondaryChange From Baseline in Scoring Atopic Dermatitis (SCORAD) Score at Week 12- LOCF

SCORAD is a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). The efficacy data were set to be missing after use of rescue medication and after early termination visit for participants who prematurely discontinued study treatment. All missing values were imputed by LOCF.

Time frame:
Baseline to Week 12
Reported as:
Mean · Units on a scale
Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Score at Week 12- LOCF
Units on a scalePlaceboDupilumab 300 mg
Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Score at Week 12- LOCF-9.8 ± 20.53-35.0 ± 19.43
SecondaryChange From Baseline in Pruritus Numerical Rating Scale (NRS) to Week 12- LOCF

Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). The efficacy data were set to be missing after use of rescue medication and after early termination visit for participants who prematurely discontinued study treatment. All missing values were imputed by LOCF.

Time frame:
Baseline to Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Pruritus Numerical Rating Scale (NRS) to Week 12- LOCF
units on a scalePlaceboDupilumab 300 mg
Change From Baseline in Pruritus Numerical Rating Scale (NRS) to Week 12- LOCF-0.9 ± 2.07-3.5 ± 2.00
SecondaryChange From Baseline in 5-D Pruritus Scale at Week 12

The 5-D Pruritus Scale is a 1-page, 5-question tool used in clinical trials to assess 5 dimensions of background itch: degree, duration, direction, disability, and distribution. Each question corresponds to 1 of the 5 dimensions of itch; participants were to rate their symptoms over the preceding 2-week period on a 1 to 5 scale, with 5 being the most affected. After the summation of individual score, the total score ranges from 5 (least affected) to 25 (most affected).

Time frame:
Baseline to Week 12
Reported as:
Mean · units on a scale
Change From Baseline in 5-D Pruritus Scale at Week 12
units on a scalePlaceboDupilumab 300 mg
Change From Baseline in 5-D Pruritus Scale at Week 12-1.9 ± 4.28-7.4 ± 4.33

Adverse events

Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Day 197) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—7/54 (13%)31/54 (57.4%)
Dupilumab 300 mg—1/55 (1.8%)38/55 (69.1%)
Most frequent serious events
Most frequent serious events
EventPlaceboDupilumab 300 mg
Dermatitis atopicSkin and subcutaneous tissue disorders4/540/55
Angina pectorisCardiac disorders1/540/55
CellulitisInfections and infestations1/540/55
Eczema herpeticumInfections and infestations1/540/55
Skin bacterial infectionInfections and infestations1/540/55
Renal failureRenal and urinary disorders1/540/55
Asthmatic crisisRespiratory, thoracic and mediastinal disorders1/540/55
Lung disorderRespiratory, thoracic and mediastinal disorders1/540/55
Facial bones fractureInjury, poisoning and procedural complications0/541/55
Most frequent other events
Showing 10 of 19
Most frequent other events
EventPlaceboDupilumab 300 mg
NasopharyngitisInfections and infestations10/5422/55
HeadacheNervous system disorders7/549/55
ConjunctivitisInfections and infestations2/548/55
Conjunctivitis allergicEye disorders0/545/55
FatigueGeneral disorders4/545/55
Injection site indurationGeneral disorders3/545/55
LymphadenopathyBlood and lymphatic system disorders4/540/55
NauseaGastrointestinal disorders4/541/55
Injection site erythemaGeneral disorders1/544/55
EosinophiliaBlood and lymphatic system disorders3/540/55

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboDupilumab 300 mgTotal
Mean39.4 ± 12.2933.7 ± 10.4136.5 ± 11.69
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboDupilumab 300 mgTotal
Female272451
Male273158
Eczema Area and Severity Index (EASI) Score
Eczema Area and Severity Index (EASI) Score(units on a scale)PlaceboDupilumab 300 mgTotal
Mean30.8 ± 13.6328.4 ± 13.5729.6 ± 13.59
Investigator's Global Assessment (IGA) Score
Investigator's Global Assessment (IGA) Score(units on a scale)PlaceboDupilumab 300 mgTotal
Mean4.0 ± 0.693.9 ± 0.673.9 ± 0.68
Scoring Atopic Dermatitis (SCORAD) Score
Scoring Atopic Dermatitis (SCORAD) Score(units on a scale)PlaceboDupilumab 300 mgTotal
Mean69.1 ± 13.3866.7 ± 13.8267.9 ± 13.59
Body Surface Area (BSA)
Body Surface Area (BSA)(percentage of BSA)PlaceboDupilumab 300 mgTotal
Mean50.8 ± 24.1346.8 ± 24.5548.8 ± 24.32
5-D Pruritus Scale
5-D Pruritus Scale(units on a scale)PlaceboDupilumab 300 mgTotal
Mean18.7 ± 3.5018.4 ± 3.0418.5 ± 3.26
Pruritus Numerical Rating Scale (NRS) Score
Pruritus Numerical Rating Scale (NRS) Score(units on a scale)PlaceboDupilumab 300 mgTotal
Mean5.8 ± 1.936.1 ± 1.345.9 ± 1.66
08

Study locations

21 sites
  • Nachod, Czechia
  • Svitavy, Czechia
  • Usti nad Labem, Czechia
  • Nice, France
  • Pierre Bénite, France
  • Toulouse, France
  • Berlin, Germany
  • Bonn, Germany
  • Frankfurt, Germany
  • Gera, Germany
  • Heidelberg, Germany
  • Kiel, Germany
  • Münster, Germany
  • Kaposvar, Hungary
  • Szeged, Hungary
  • Szekszard, Hungary
  • Szolnok, Hungary
  • Gdansk, Poland
  • Lodz, Poland
  • Lublin, Poland
  • Warszawa, Poland
09

References and documents

Publications

  • Beck LA, Thaci D, Hamilton JD, Graham NM, Bieber T, Rocklin R, Ming JE, Ren H, Kao R, Simpson E, Ardeleanu M, Weinstein SP, Pirozzi G, Guttman-Yassky E, Suarez-Farinas M, Hager MD, Stahl N, Yancopoulos GD, Radin AR. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014 Jul 10;371(2):130-9. doi: 10.1056/NEJMoa1314768. PubMed 25006719 ↗
  • Tsianakas A, Luger TA, Radin A. Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial. Br J Dermatol. 2018 Feb;178(2):406-414. doi: 10.1111/bjd.15905. Epub 2018 Jan 11. PubMed 28845523 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Mar 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2018, 5 years 5 months after primary completion. A results delay was requested in Aug 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2012
First posted
Mar 8, 2012
Start
Apr 2012
Primary completionActual
Mar 2013
CompletionActual
Jun 2013
Results delay requested
Aug 27, 2015
Results first posted
Aug 10, 2018
Last update
Aug 10, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01548404
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Mar 8, 2012
Start date
Apr 2012
Primary completion
Mar 2013
Completion
Jun 2013
Results posted
Aug 10, 2018
Last update
Aug 10, 2018

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion